Literature DB >> 16824744

Breath-holding test in subjects with near-fatal asthma. A new index for dyspnea perception.

L J Nannini1, G A Zaietta, A J Guerrera, J A Varela, O M Fernández, D M Flores.   

Abstract

RATIONALE: Identification of asthmatic subjects with low perception of dyspnea (POD) that are at higher risk of hospitalization, near-fatal and fatal asthma could improve their management.
OBJECTIVE: Create a simple procedure that facilitate the recognition of low POD.
METHODS: We enrolled near fatal asthma (NFA) subjects and a wide spectrum of non-NFA subjects. Each subject was asked to stop breathing at end-expiration. Dyspnea was assesssed by a modified Borg scale. To design the new index, we combined the Borg score at the end of the voluntary breath-holding maneuver with the airway limitation. The equation was as follows: FEV(1)/FVC%/(breath-holding time in seconds/final Borg score minus basal Borg score).
RESULTS: Eleven NFA subjects (4 females) aged 21-73yr and 55 non-NFA (14 severe, 18 moderate and 23 mild asthmatic subjects) completed the study. The threshold value of the index that could predict POD is <12. The mean (+/-sd) of the new index perception was significantly lower in NFA group (n=11; 5.21+/-3.59; vs. n=55; 13.67+/-11.08; P=0.006). This threshold value had 100% sensitivity and it best discriminated between mild and NFA groups. The negative likelihood ratio (when the index > or = 12) was zero. A result > or = 12 represented an almost null probability of poor POD.
CONCLUSION: The breath-holding test is simple and rapid. Its negative likelihood ratio was zero. Accordingly, a test result of 12 or greater might exclude the probability of poor perception of dyspnea in subjects with stable asthma.

Entities:  

Mesh:

Year:  2006        PMID: 16824744     DOI: 10.1016/j.rmed.2006.05.013

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  7 in total

Review 1.  Management of acute asthma in adults in the emergency department: nonventilatory management.

Authors:  Rick Hodder; M Diane Lougheed; Brian H Rowe; J Mark FitzGerald; Alan G Kaplan; R Andrew McIvor
Journal:  CMAJ       Date:  2009-10-26       Impact factor: 8.262

2.  Maximal Voluntary Breath-Holding Tele-Inspiratory Test in Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Abir Hedhli; Azza Slim; Yassine Ouahchi; Meriem Mjid; Jamel Koumenji; Sana Cheikh Rouhou; Sonia Toujani; Besma Dhahri
Journal:  Am J Mens Health       Date:  2021 May-Jun

3.  Impact of blunted perception of dyspnea on medical care use and expenditure, and mortality in elderly people.

Authors:  Satoru Ebihara; Kaijun Niu; Takae Ebihara; Shinichi Kuriyama; Atsushi Hozawa; Kaori Ohmori-Matsuda; Naoki Nakaya; Ryoichi Nagatomi; Hiroyuki Arai; Masahiro Kohzuki; Ichiro Tsuji
Journal:  Front Physiol       Date:  2012-07-04       Impact factor: 4.566

4.  Effect of Dyspnea Induced by Breath-holding on Maximal Muscular Strength of Patients with COPD.

Authors:  Kazuya Shingai; Masashi Kanezaki
Journal:  J Phys Ther Sci       Date:  2014-02-28

5.  Factors associated with discrepancies between poor dyspnea perception and abnormal lung function in 65 asthmatic patients.

Authors:  Asmaa Jniene; Leila Achachi; Mustapha El Bakkali; Laila Herrak; Aziza Rhanim; Souad Aboudrar; Taoufiq Dakka; Mustapha El Ftouh
Journal:  Afr Health Sci       Date:  2020-09       Impact factor: 0.927

6.  Validation of a breath-holding test as a screening test for exercise-induced hypoxemia in chronic respiratory diseases.

Authors:  Hideharu Ideguchi; Hidenori Ichiyasu; Kazuaki Fukushima; Hiroko Okabayashi; Kimitaka Akaike; Shohei Hamada; Kazuyoshi Nakamura; Susumu Hirosako; Hirotsugu Kohrogi; Takuro Sakagami; Kazuhiko Fujii
Journal:  Chron Respir Dis       Date:  2021 Jan-Dec       Impact factor: 2.444

7.  Utility of the breath-holding test in patients with systemic sclerosis.

Authors:  Jina Yeo; Ju Yeon Kim; Mi Hyeon Kim; Jun Won Park; Jin Kyun Park; Eun Bong Lee
Journal:  Rheumatology (Oxford)       Date:  2022-10-06       Impact factor: 7.046

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.